Published in Hepatology on April 01, 2014
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology (2015) 1.09
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol (2016) 1.07
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. Adv Ther (2015) 1.06
Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med (2015) 0.97
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir. Infect Dis Ther (2014) 0.93
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol (2016) 0.90
Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog (2015) 0.90
Update on hepatitis C: Direct-acting antivirals. World J Hepatol (2015) 0.88
Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev (2016) 0.88
Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLoS One (2015) 0.86
Daclatasvir. Aust Prescr (2015) 0.85
Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol (2014) 0.84
Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm (2016) 0.83
HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses (2015) 0.83
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol (2015) 0.82
Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol (2015) 0.82
Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. PLoS One (2015) 0.81
Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol (2016) 0.81
New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res (2014) 0.80
Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol (2016) 0.80
Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol (2015) 0.80
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. BMC Nephrol (2017) 0.80
Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol (2015) 0.79
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health (2015) 0.79
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol (2016) 0.79
Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol (2016) 0.79
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol (2015) 0.78
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol (2015) 0.78
Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer (2016) 0.78
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother (2015) 0.78
Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. J Gastroenterol (2016) 0.78
Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol (2015) 0.78
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon (2016) 0.78
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One (2016) 0.78
Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World J Gastroenterol (2015) 0.78
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol (2016) 0.78
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J Gastroenterol (2015) 0.78
Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases (2016) 0.77
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag (2014) 0.77
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. J Gastroenterol (2016) 0.77
Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther (2015) 0.76
Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol (2015) 0.76
Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep (2016) 0.76
Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Sci Rep (2017) 0.75
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol (2017) 0.75
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep (2017) 0.75
A Review of Daclatasvir Drug-Drug Interactions. Adv Ther (2016) 0.75
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol (2016) 0.75
Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver (2016) 0.75
A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med (2015) 0.75
Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Sci Rep (2017) 0.75
Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. J Clin Transl Hepatol (2016) 0.75
Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions. Intern Med (2016) 0.75
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol (2017) 0.75
Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. J Clin Transl Hepatol (2016) 0.75
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol (2016) 0.75
Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol (2015) 0.75
Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med (2016) 0.75
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis (2015) 0.75
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One (2016) 0.75
Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol (2017) 0.75
Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case Rep Gastroenterol (2016) 0.75
Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report. Case Rep Gastroenterol (2016) 0.75
Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Gut Liver (2016) 0.75
Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol (2015) 0.75
Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. PLoS One (2016) 0.75
Asunaprevir. Aust Prescr (2015) 0.75
Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo. Biomed Rep (2016) 0.75
Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases (2015) 0.75
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS One (2015) 0.75
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci (2016) 0.75
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol (2016) 0.75
A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep (2016) 0.75
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol (2017) 0.75
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol (2017) 0.75
Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir. J Gastroenterol (2016) 0.75
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One (2017) 0.75
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. J Gastroenterol (2017) 0.75
Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol (2017) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol (2013) 1.80
Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat (2011) 1.37
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis (2010) 1.34
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Mapping human genetic diversity in Asia. Science (2009) 7.40
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc (2006) 5.42
Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med (2002) 5.30
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet (2009) 5.29
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology (2004) 4.16
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis (2012) 3.91
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol (2011) 3.88
Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology (2002) 3.79
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology (2012) 3.54
Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol (2005) 3.51
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet (2011) 3.19
Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol (2007) 3.14
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J (2002) 3.06
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 3.01
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA (2007) 3.00
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation (2003) 2.69
Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization. Gastrointest Endosc (2007) 2.62
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis (2012) 2.41
Single-balloon versus double-balloon endoscopy for achieving total enteroscopy: a randomized, controlled trial. Gastrointest Endosc (2011) 2.39
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology (2013) 2.36
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol (2012) 2.34
Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol (2009) 2.31
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer (2003) 2.29
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol (2012) 2.24
A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: a retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest Endosc (2009) 2.24
Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002) 2.23
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer (2010) 2.20
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell (2012) 2.14
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol (2012) 2.14
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer (2002) 2.13
Clinical features of pharyngeal intraepithelial neoplasias and outcomes of treatment by endoscopic submucosal dissection. Gastrointest Endosc (2012) 2.12
The origin and evolution of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol (2005) 2.09
Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer (2011) 2.09
Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet (2011) 2.09
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet (2005) 2.08
Activation of STAT6 by STING is critical for antiviral innate immunity. Cell (2011) 2.08
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol (2005) 2.07
Detectability of colorectal neoplasia with fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT). J Gastroenterol (2011) 2.07
A large variation in the rates of synonymous substitution for RNA viruses and its relationship to a diversity of viral infection and transmission modes. Mol Biol Evol (2004) 2.07
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol (2008) 2.06
Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc (2007) 2.04